ALK and adenosquamous lung carcinoma: Here, we report a case of lung adenosquamous carcinoma that recurred after surgical resection, harboring a novel 5′ NOK fusion form, ALK-CYP27C1, which benefited from the ALK inhibitor ensartinib.